Navigation Links
First Warning Systems Receives Investment by Members of the Reno Angels and Local Investors
Date:8/6/2012

RENO, Nev., Aug. 6, 2012 /PRNewswire/ -- First Warning Systems, Inc. announces members of the Reno Angels have joined together with local investors to invest in the First Warning Systems $1,000,000 Series A funding round. 

Jim Holmes, First Warning's CEO states, "We are approaching fifty percent completion of this Series A round of financing.  We appreciate members of the Reno Angels and local investors' support of the First Warning System." 

For particulars concerning the Series A round, please check First Warning's website: www.firstwarningsystems.com/series-a-funding.html.

The First Warning patented technology uses predictive analytics software to penetrate imaging technology barriers that are limited to viewing a tumor that, on average, has been growing for 11 years.  Deep tissue temperature analysis from 12 hours of dynamic data collection is modeled using predictive analytics software to compare circadian body rhythms that can identify abnormalities up to 6 years prior to imaging technologies. The First Warning product vision video can be seen at www.firstwarningsystems.com

Holmes adds, "We are planning the establishment of a production facility for our products, determining employee requirements to support worldwide marketing and sales.  We are investigating and hopeful of being able to establish these operations in the Truckee Meadows area."        

About First Warning Systems

First Warning Systems, (FWS) founded in 2008, is based in Reno, NV.  FWS' principal shareholder is Lifeline Biotechnologies, Inc. (OTC Market: LLBO). FWS holds the exclusive worldwide license from Lifeline Biotechnologies for development, manufacturing and marketing of the software-based technologies. The FWS product line is a patented device and process that detects breast tissue abnormalities for health risk assessment and management earlier than any other known modalities.  These tissue abnormalities can lead to breast cancers. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes with industry leading 90% accuracy.  FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS predictive analytics product.  FWS is preparing for Euro CE Mark and marketing in the UK, EU and Russian markets.  For more information check www.firstwarningsystems.com

For more information, contact: Jim Holmes, CEO 775-324-3822 or 775-852-3222, jholmes@firstwarningsystems.com 


'/>"/>
SOURCE First Warning Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2012
2. Midwest Health Care Startups Raise $511 Million in First Half of 2012
3. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
4. Target for potent first-strike influenza drugs identified
5. Genelex Receives First Patent on Business Methods for Pharmacogenetics
6. TI introduces the industrys first weigh scale and body composition analog front end
7. Midwest Health Care Startups Raise $491 Million in First Half of 2012
8. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
9. Abaxis Reports Financial Performance For The First Quarter Of Fiscal 2013
10. AHIMA Launches First HIM Career Map
11. MIOT Hospital Delivers First TrueBeam STx Radiotherapy Treatment in Chennai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 ... ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron ... announced the signing of a three-year exclusive sales ... deploy a dedicated sales team to introduce Imprimis, ... primarily focused in 13 states in the U.S. ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 2017 , ... Contrary to popular perception, a new study ... noteworthy rates. Between 2002 and 2014, Salas-Wright and his colleagues found a 29% ... United States. The study, Trends in Fighting and Violence Among Adolescents in ...
(Date:4/21/2017)... ... ... Dudnyk has announced the launch of its new brand identity, called The ... specialty and orphan brands can only be achieved when the needs and beliefs of ... at the heart of a true partnership between our agency and our clients to ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... performance system, has partnered with O2X , an active lifestyle company that ... on improving the health of firefighters, police offers, first responders, military officers and ...
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured ... Trade, the UK’s most prestigious award for business success. The company has ... revenues and has grown by a total of 400% over the last six ...
(Date:4/21/2017)... Abilene, Texas (PRWEB) , ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... out to world leaders in hopes of squashing a global crisis with solution to peace ... is guaranteed to work because the plan is given by the Creator Himself. , ...
Breaking Medicine News(10 mins):